Rethinking the Management of Differentiated and Anaplastic Thyroid Cancers

To claim CME credit, visit https://i3health.com/oda-thyroid While thyroid cancer is the most common endocrine cancer, prognosis and survival rates vary widely by subtype. This episode of Oncology Data Advisor will focus on advances in the management of differentiated and anaplastic thyroid cancers. It features perspectives from two noted experts in the field: Dr. Jochen Lorch, Director of the Thyroid Cancer Center at Dana-Farber Cancer Institute; and Ms. Carolyn Grande, Oncology Nurse Practitioner at Abramson Cancer Center. This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com. Free CME and NCPD credit are available for this podcast. To claim credit and obtain further information, including faculty disclosures, visit i3Health.com/ODA-thyroid.